Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Andreas Sashegyi"'
Autor:
Hannah M Davis, Jürgen Wolf, Keunchil Park, Boris Lin, Herbert H. Loong, Benjamin Solomon, Maurice Pérol, Fernando C. Santini, Victoria Soldatenkova, Alexander Drilon, Silvia Novello, Edurne Arriola, Koichi Goto, Aimee Bence Lin, C. Zhou, Yasir Elamin, Andreas Sashegyi
Publikováno v:
Future Oncology. 17:763-773
Selpercatinib, a novel, highly selective and potent, inhibitor of RET, demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pretreated and treatment-naive RET fusion-positive non-small-cell lung cancer patients in
Autor:
Jin-Yuan Shih, Katherine B. Winfree, Frances A. Shepherd, Rebecca Cheng, Martin Reck, Pablo Lee, R. Varea, Andreas Sashegyi, Mark A. Socinski, Marina Chiara Garassino, Martina Imbimbo, Anne Tsao, Benjamin Levy, Edward B. Garon
Publikováno v:
Lung Cancer. 120:62-69
A majority of patients with advanced or metastatic non-small cell lung cancer (NSCLC) will experience disease progression after first-line therapy. Patients who have advanced NSCLC that is especially aggressive, which is defined as disease that rapid
Autor:
Ian Chau, David Ferry, Manjulika Das, Luis Paz-Ares, John R. Mackey, Ari David Baron, Andrew X. Zhu, Andreas Sashegyi, A. Ohtsu, Josep Tabernero, Edward B. Garon, Takuji Okusaka, Polina Binder, Charles S. Fuchs, Dirk Arnold, Harry H. Yoon, Yong Lin, Takayuki Yoshino, Yawei Zhang
Publikováno v:
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Recercat. Dipósit de la Recerca de Catalunya
instname
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Annals of Oncology
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Recercat. Dipósit de la Recerca de Catalunya
instname
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Annals of Oncology
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Background Ramucirumab, the human immunoglobulin G1 monoclonal antibody receptor antagonist of vascular endothelial growth factor receptor 2, has been approved for treating gastric/gastroesophageal junction, non-small-cell lung, and metastatic colore
Autor:
A. Drilon, C. Zhou, A. Bence Lin, Juergen Wolf, Boris Lin, Ben Solomon, Fernando C. Santini, E. Arriola Aperribay, Maurice Pérol, Yasir Elamin, Victoria Soldatenkova, Koichi Goto, Andreas Sashegyi, K. Park, Silvia Novello, Herbert H. Loong
Publikováno v:
Journal of Thoracic Oncology. 16:S228-S229
Autor:
V. Tarasova, Victoria Soldatenkova, J. Hernando, Andreas Sashegyi, Ana O. Hoff, Jennifer Wright, Lori J. Wirth, Makoto Tahara, R. Elisei, Sophie Leboulleux, Jaume Capdevila, Mimi Hu, Marcia S. Brose, Eric J. Sherman, Boris Lin, Bruce G. Robinson
Publikováno v:
Annals of Oncology. 31:S1091
Autor:
Yasir Elamin, Geoffrey R. Oxnard, Victoria Soldatenkova, Juergen Wolf, Andreas Sashegyi, C. Zhou, Herbert H. Loong, A. Drilon, Fernando C. Santini, K. Park, Boris Lin, Ben Solomon, Koichi Goto, A. Bence Lin
Publikováno v:
Annals of Oncology. 31:S893
Autor:
Boris Lin, Andreas Sashegyi, Benjamin Solomon, Pearl Plernjit French, Yvonne Summers, Alexander Drilon, Zachary M Thomas, Herbert H. Loong, Juergen Wolf, James Chih-Hsin Yang
Publikováno v:
Journal of Clinical Oncology. 38:3588-3588
3588 Background: Randomized trials involving agents targeting oncogene addicted tumors have greatly increased over the past decade. Whether clinical response rates can predict or correlate with efficacy measures such as progression-free survival (PFS
Autor:
Eun Kyung Cho, M Kimmich, Nina Karaseva, Oliver Gautschi, Edward B. Garon, Ekaterine Alexandris, Ruben Dario Kowalyszyn, Maurice Pérol, Pablo Lee, Martin Reck, Katherine B. Winfree, Shaker R. Dakhil, Gebra Cuyun Carter, Annamaria Zimmerman, Andreas Sashegyi, Grzegorz Czyzewicz, Alexandru Grigorescu, Suresh S. Ramalingam
Publikováno v:
Clinical lung cancer. 19(3)
Introduction Ramucirumab, a recombinant human immunoglobulin G1 monoclonal antibody receptor antagonist designed to block the ligand-binding site of vascular endothelial growth factor receptor-2 (VEGFR-2), was evaluated as second-line treatment in co
Autor:
Martin Reck, Denis Moro-Sibilot, Paolo Bidoli, Annamaria Zimmermann, Michael Thomas, Melissa Lynne Johnson, Luis Paz-Ares, Pablo Lee, Robert M. Jotte, Anne Tsao, Nathan A. Pennell, Faye W. Chan-Diehl, Ekaterine Alexandris, Federico Cappuzzo, Maurice Pérol, Frances A. Shepherd, Hossein Borghaei, Gebra Cuyun Carter, Andreas Sashegyi, Shaker R. Dakhil
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 112
Objectives The REVEL study demonstrated improved efficacy for patients with advanced non-small cell lung cancer treated with ramucirumab plus docetaxel, independent of histology. This exploratory analysis characterized the treatment effect in REVEL p
Publikováno v:
Journal of Multi-Criteria Decision Analysis. 21:139-151
Taking decisions during the development of a new drug requires combining many and varying pieces of information. The interconnections between these different pieces of information are often only partially known and in some cases merely conjectured. D